Role of beliefs in predicting adherence to nebulised therapy in CF

  • Research type

    Research Study

  • Full title

    The role of beliefs in predicting adherence to nebulised therapy in adolescents with cystic fibrosis.

  • IRAS ID

    249889

  • Contact name

    Bronwyn Stirzaker

  • Contact email

    umbms@leeds.ac.uk

  • Sponsor organisation

    Univeristy of Leeds

  • Clinicaltrials.gov Identifier

    n/a, n/a

  • Duration of Study in the UK

    0 years, 5 months, 15 days

  • Research summary

    The biggest challenge to improving healthcare outcomes is poor adherence (i.e. patients not taking their medication as prescribed). In cystic fibrosis (CF), adherence is especially poor in nebulised treatments and in the adolescent population leading to poor medical outcomes. The factors that underlie this problem are under-researched.\n\nIn other chronic conditions treatment beliefs have been found to influence adherence behaviour, and effective interventions that target problematic beliefs have been developed. These studies examined beliefs using the Beliefs about Medicines Questionnaire (BMQ).\n\nThe present study plans to extend a previous study that used the BMQ to examine whether adolescent and parent treatment beliefs affect nebulised therapy adherence. \n\nIt extends the study by:\n\n1: tailoring the BMQ for use in CF with the two types of nebulised medications (mucolytics and antibiotics) commonly used. We will ask a patient, a parent and professionals to help develop these two adapted questionnaires in two linked online Delphi surveys. These will take approximately 15-20 minutes and will be sent 14-30 days apart. The patient will be aged 16-17 and will have used these medications in the past year, while the professionals will be physiotherapists who have worked in CF for at least a year, and who support patients to adhere to these medications.\n\n2: the main study will examine whether the original and revised BMQ questionnaires relate to adherence behaviour. Patients and parents will be recruited from Leeds, Liverpool and Sheffield paediatric CF centres. Patients must be aged 12-17 years and be using I-nebulisers (devices which deliver medication and automatically record adherence) daily. The study will be completed during routine outpatient appointments. In the first appointment, patients and parents/guardians will be asked to complete the belief questionnaires, and in the second appointment, I-nebuliser data will be downloaded.

  • REC name

    Yorkshire & The Humber - Leeds West Research Ethics Committee

  • REC reference

    18/YH/0496

  • Date of REC Opinion

    21 Dec 2018

  • REC opinion

    Favourable Opinion